Supplementary Table 1. Baseline, Week 17 and change from baseline to Week 17 in pulmonary vascular resistance (per protocol and all-treated set)

	Mean values ± SD at baseline		Mean values ± SD at Week 17		Mean change ± SD from baseline to Week 17		Treatment effect* [95% CL; Wilcoxon *P*-value]
	Placebo	Selexipag	Placebo	Selexipag	Placebo	Selexipag	
Per protocol set							
N	6	29	6	29	6	29	
Pulmonary vascular resistance, dyn · s · cm^{-5}	826.8±195.8	951.9±434.5	964.0±247.9	783.8±393.2	137.2 ± 84.9	−168.1 ± 241.6	−30.3% [−44.7, −12.2; 0.0045]
All-treated set							
N	10	32	10	32	10	32	
Pulmonary vascular resistance, dyn · s · cm^{-5}	867.2 ± 379.3	948.6 ± 428.0	1090.8 ± 421.3	818.8 ± 416.9	223.6 ± 355.4	−129.8 ± 309.7	−33.0% [−47.0, −15.2; 0.0022]

*Treatment effect calculated at Week 17 as the change in the geometric mean expressed as a percentage of the baseline value
SD; standard deviation

Supplementary Table 2. Serious adverse events during the study (safety set)

Serious adverse events	Placebo n=10	Selexipag n=33
Patients with ≥1 serious adverse event, n	4	6
Total number of serious adverse events	10	13
Headache	-	2
Pulmonary arterial hypertension	2	1
Dyspnoea	1	1
Chest pain	-	1
Myalgia	-	1
Nasopharyngitis	-	1
Nausea	-	1
Oral papilloma	-	1
Psychotic disorder	-	1
Sciatica	-	1
Urinary tract infection	-	1
Vomiting	-	1
Alcohol interaction	1	-
Benign prostatic hyperplasia	1	-
Cardiac failure	1	-

Cataract operation	1	-
Chronic obstructive pulmonary disease	1)	-
Respiratory infection	1	-
Urinary retention	1	-

Supplementary Table 3. Prevalence of selected treatment-emergent adverse events over time in selexipag-treated patients

Adverse events (AE)*	**≥0–27 days (n=33)**	**≥28–55 days (n=32)**	**≥56–83 days (n=32)**	**≥84 days (n=31)**
Patients with ≥1 AE, n (%)	26 (78.8)	24 (75.0)	22 (68.8)	21 (67.7)
Different AEs, n	56	47	43	34
AE, n (%)				
Headache	21 (63.6)	16 (50.0)	16 (50.0)	14 (45.2)
Pain in extremity	10 (30.3)	9 (28.1)	9 (28.1)	4 (12.9)
Pain in jaw	8 (24.2)	8 (25.0)	6 (18.8)	6 (19.4)
Nausea	8 (24.2)	6 (18.8)	5 (15.6)	4 (12.9)
Flushing	4 (12.1)	4 (12.5)	4 (12.5)	4 (12.9)
Diarrhoea	5 (15.2)	4 (12.5)	3 (9.4)	2 (6.5)

*Adverse events commonly associated with prostacyclin analogues